



ASX Announcement

Encouraging Interim Data from Phase 1b Ovarian Cancer Trial with PTX-200

Melbourne, Australia - 12 December 2019: Prescient Therapeutics Limited (ASX: PTX) ("Prescient"), a clinical stage company developing personalised medicine approaches to cancer, is pleased to announce positive interim data from the Phase 1b safety study of PTX-200 in women with recurrent or persistent platinum resistant ovarian cancer, with acceptable safety and 80% of women exhibiting disease control (being partial response or stable disease).

The primary aim of the Phase 1b study is to find the maximum tolerated dose of PTX-200 in combination with carboplatin and is led by principal investigator Dr Robert Wenham at the H. Lee Moffitt Cancer Center in Florida, United States. 15 women with recurrent or persistent platinum resistant ovarian cancer have been recruited to the study and treated with 15-25mg/m² of PTX-200, together with carboplatin.

Analysis of the interim data revealed that 12 of 15 patients (80%) exhibited disease control, with 11 women exhibiting stable disease and one patient having a partial response. Escalation has not yet been completed and Prescient believes that it has not yet escalated to the optimal dose of PTX-200.

There were seven serious adverse events reported across the 15 patients, but only one of these was considered possibly related to PTX-200, being a case of grade 2 vomiting that resulted in hospitalisation.

Ovarian cancer patients who become resistant to front-line platinum-based chemotherapy, such as carboplatin, are left with very few clinical options. It is known that aberrantly high Akt contributes to this platinum resistance. The rationale of this study is to inhibit Akt, and thereby re-sensitise these patients to platinum therapies, effectively reversing and overcoming resistance of the tumour to chemotherapy. Pre-clinical studies have already proven that PTX-200 can overcome platinum resistance and can synergise with platinum-based chemotherapies.

Prescient's Chief Medical Officer, Dr Terry Chew, said "At the time of entering the study, these ovarian cancer patients are unresponsive to platinum-based chemotherapy, which is standard of care. Therefore, to see disease control at this stage of the study is encouraging, especially given that we are yet to reach what we believe to be an optimal dose of PTX-200. Furthermore, the safety profile of PTX- in this combination appears acceptable so far, with observed toxicities consistent with what is seen using carboplatin alone."

Prescient Therapeutics CEO, Steven Yatomi-Clarke said, "Ovarian cancer remains one of the most common cancers in women, with very poor clinical outcomes. After initial platinum chemotherapy, a significant majority of women relapse, and are deemed platinum resistant. At this stage of disease, there are very few clinical options for these patients, and a severe gap in the market for new drugs for platinum resistant cancers. Overcoming platinum resistance would therefore be a huge development in the field of ovarian cancer, and PTX-200 is showing early promise as a candidate that could achieve this objective."

"As foreshadowed, in the interests of mitigating the rising costs of conducting clinical trials overseas, Prescient will seek to continue studying PTX-200 in ovarian cancer in Australia and/or as an investigator sponsored study backed by non-dilutive funding. We look forward to building on the encouraging results we have seen so far in this study".

Ends

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only RhoA inhibitor in the world in clinical development. PTX-100 is currently in a PK/PD basket study of hematological and solid malignancies, focusing on cancers with Ras and RhoA mutations. In a previous Phase 1 trial in advanced solid tumors, PTX-100 was well tolerated and achieved stable disease.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound has encouraging Phase 2a data in HER2-negative breast cancer; Phase 1b/2 in relapsed and refractory AML and Phase 1b in recurrent or persistent platinum resistant ovarian cancer:

Cell Therapy: Prescient has a collaboration with Carina Biotech developing new CAR-T therapy approaches.

Find out more at ptxtherapeutics.com, or connect with us via Twitter [@PTX_AUS](https://twitter.com/PTX_AUS) and [LinkedIn](https://www.linkedin.com/company/ptxtherapeutics).

For and on behalf of the Board and for more information please contact:

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics Limited
+61 417 601 440

Andrew Geddes
CityPR
+61 2 9267 4511

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited (“Prescient” or the “Company”), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words ‘estimate’, ‘project’, ‘intend’, ‘expect’, ‘plan’, ‘believe’, ‘guidance’, and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management’s current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.